Abstract
Introduction
Low potassium intake can affect cardiovascular disease (CVD) risk and cardiometabolic risk factors.
Objective
We hypothesize that potassium chloride (KCl) supplementation can improve cardiovascular risk metabolomic profile.
Methods
In this secondary analysis of a pilot randomized clinical trial (RCT) of 26 participants with prediabetes randomized to KCl or placebo, we performed targeted mass-spectrometry-based metabolomic profiling on baseline and 12-week (end-of-study) plasma samples. Principal component analysis (PCA) was used to reduce the many correlated metabolites into fewer, independent factors that retain most of the information in the original data.
Results
Those taking KCl had significant reductions (corresponding to lower cardiovascular risk) in the branched-chain amino acids (BCAA) factor (P = 0.004) and in valine levels (P = 0.02); and non-significant reductions in short-chain acylcarnitines (SCA) factor (P = 0.11).
Conclusions
KCl supplementation may improve circulating BCAA levels, which may reflect improvements in overall cardiometabolic risk profile.
Clinical Trials Registry
Clinicaltrials.gov identifier: NCT02236598; https://clinicaltrials.gov/ct2/show/NCT02236598.
Data availability
De-identified data described in the manuscript, code book, and analytic code will be made available upon review of requests.
Abbreviations
- A1c:
-
Hemoglobin A1c
- BCAA:
-
Branched-chain amino acids
- CVD:
-
Cardiovascular disease
- IQR:
-
Interquartile range
- KCl:
-
Potassium chloride
- LCA:
-
Long-chain acylcarnitines
- OGTT:
-
Oral glucose tolerance test
- PCA:
-
Principal component analysis
- SCA:
-
Short-chain acylcarnitines
References
Abdulla, H., Smith, K., Atherton, P. J., & Idris, I. (2016). Role of insulin in the regulation of human skeletal muscle protein synthesis and breakdown: A systematic review and meta-analysis. Diabetologia,59, 44–55.
Aburto, N. J., Hanson, S., Gutierrez, H., Hooper, L., Elliott, P., & Cappuccio, F. P. (2013). Effect of increased potassium intake on cardiovascular risk factors and disease: Systematic review and meta-analyses. BMJ,346, f1378.
Chatterjee, R., Slentz, C., Davenport, C. A., Johnson, J., Lin, P. H., Muehlbauer, M., et al. (2017). Effects of potassium supplements on glucose metabolism in African Americans with prediabetes: A pilot trial. American Journal of Clinical Nutrition,106, 1431–1438.
Chatterjee, R., Yeh, H. C., Shafi, T., Selvin, E., Anderson, C., Pankow, J. S., et al. (2010). Serum and dietary potassium and risk of incident type 2 diabetes mellitus: The Atherosclerosis Risk in Communities (ARIC) Study. Archives of Internal Medicine,170, 1745–1751.
Filippini, T., Violi, F., D'Amico, R., & Vinceti, M. (2017). The effect of potassium supplementation on blood pressure in hypertensive subjects: A systematic review and meta-analysis. International Journal of Cardiology,230, 127–135.
Guasch-Ferre, M., Hruby, A., Toledo, E., Clish, C. B., Martinez-Gonzalez, M. A., Salas-Salvado, J., et al. (2016a). Metabolomics in prediabetes and diabetes: A systematic review and meta-analysis. Diabetes Care,39, 833–846.
Guasch-Ferre, M., Hu, F. B., Ruiz-Canela, M., Bullo, M., Toledo, E., Wang, D. D., et al. (2017). Plasma metabolites from choline pathway and risk of cardiovascular disease in the PREDIMED (prevention with mediterranean diet) study. Journal of the American Heart Association,6, e006524.
Guasch-Ferre, M., Zheng, Y., Ruiz-Canela, M., Hruby, A., Martinez-Gonzalez, M. A., Clish, C. B., et al. (2016b). Plasma acylcarnitines and risk of cardiovascular disease: Effect of Mediterranean diet interventions. American Journal of Clinical Nutrition,103, 1408–1416.
Kalhan, S. C. (2009). Fatty acids, insulin resistance, and protein metabolism. Journal of Clinical Endocrinology and Metabolism,94, 2725–2727.
Kraus, W. E., Granger, C. B., Sketch, M. H., Jr., Donahue, M. P., Ginsburg, G. S., Hauser, E. R., et al. (2015). A guide for a cardiovascular genomics biorepository: The CATHGEN experience. Journal of Cardiovascular Translational Research,8, 449–457.
Mente, A., O'Donnell, M. J., Rangarajan, S., McQueen, M. J., Poirier, P., Wielgosz, A., et al. (2014). Association of urinary sodium and potassium excretion with blood pressure. New England Journal of Medicine,371, 601–611.
Newgard, C. B., An, J., Bain, J. R., Muehlbauer, M. J., Stevens, R. D., Lien, L. F., et al. (2009). A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metabolism,9, 311–326.
O'Donnell, M., Mente, A., Rangarajan, S., McQueen, M. J., Wang, X., Liu, L., et al. (2014). Urinary sodium and potassium excretion, mortality, and cardiovascular events. New England Journal of Medicine,371, 612–623.
Peng, Y., Zhong, G. C., Mi, Q., Li, K., Wang, A., Li, L., et al. (2017). Potassium measurements and risk of type 2 diabetes: A dose-response meta-analysis of prospective cohort studies. Oncotarget,8, 100603–100613.
Rebholz, C. M., Lichtenstein, A. H., Zheng, Z., Appel, L. J., & Coresh, J. (2018). Serum untargeted metabolomic profile of the dietary approaches to stop hypertension (DASH) dietary pattern. American Journal of Clinical Nutrition,108, 243–255.
Ruiz-Canela, M., Guasch-Ferre, M., Toledo, E., Clish, C. B., Razquin, C., Liang, L., et al. (2018). Plasma branched chain/aromatic amino acids, enriched Mediterranean diet and risk of type 2 diabetes: Case-cohort study within the PREDIMED Trial. Diabetologia,61, 1560–1571.
Ruiz-Canela, M., Hruby, A., Clish, C. B., Liang, L., Martinez-Gonzalez, M. A., & Hu, F. B. (2017). Comprehensive metabolomic profiling and incident cardiovascular disease: A systematic review. Journal of the American Heart Association,6, e005705.
Shah, S. H., Bain, J. R., Muehlbauer, M. J., Stevens, R. D., Crosslin, D. R., Haynes, C., et al. (2010a). Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circulation: Cardiovascular Genetics,3, 207–214.
Shah, S. H., Crosslin, D. R., Haynes, C. S., Nelson, S., Turer, C. B., & Stevens, R. D., et al. (2012). Branched-chain amino acid levels are associated with improvement in insulin resistance with weight loss. Diabetologia,55, 321–330.
Shah, S. H., Granger, C. B., Hauser, E. R., Kraus, W. E., Sun, J. L., Pieper, K., et al. (2010b). Reclassification of cardiovascular risk using integrated clinical and molecular biosignatures: Design of and rationale for the Measurement to Understand the Reclassification of Disease of Cabarrus and Kannapolis (MURDOCK) Horizon 1 Cardiovascular Disease Study. American Heart Journal,160, 371–379.e2.
Shah, S. H., Hauser, E. R., Bain, J. R., Muehlbauer, M. J., Haynes, C., & Stevens, R. D., et al. (2009). High heritability of metabolomic profiles in families burdened with premature cardiovascular disease. Molecular Systems Biology,5, 258.
Tobias, D. K., Lawler, P. R., Harada, P. H., Demler, O. V., Ridker, P. M., Manson, J. E., et al. (2018). Circulating branched-chain amino acids and incident cardiovascular disease in a prospective cohort of US women. Circulation: Genomic and Precision Medicine,11, e002157.
Walford, G. A., Ma, Y., Clish, C., Florez, J. C., Wang, T. J., Gerszten, R. E., et al. (2016). Metabolite profiles of diabetes incidence and intervention response in the diabetes prevention program. Diabetes,65, 1424–1433.
Wang, H., Anstrom, K., Ilkayeva, O., Muehlbauer, M. J., Bain, J. R., & Mcnulty, S., et al. (2017). Sildenafil treatment in heart failure with preserved ejection fraction: Targeted metabolomic profiling in the RELAX Trial. JAMA Cardiology,2, 896–901.
White, P. J., & Newgard, C. B. (2019). Branched-chain amino acids in disease. Science,363, 582–583.
Acknowledgements
We thank the participants who were very much invested in and supportive of the trial and the biorepository, which allowed for this study.
Funding
National Institutes of Health/Clinical and Translational Science Award at Duke UL1TR002553 (CAD). National Institutes of Health/Duke Clinical and Translational Science award KL2TR001115-02 (RC); National Institutes of Health/Clinical and Translational Core for the Duke O’Brien Center for Kidney Research, award 1P30DK096493-03 (RC). National Institutes of Health R01-HL127009 (Sha).
Author information
Authors and Affiliations
Contributions
RC, LPS, DD, PHL, DE, SHS designed research (project conception, development of overall research plan, and study oversight); RC, CAD, CS, JJ, OI, LK conducted research (hands-on conduct of the experiments and data collection); OI, LK provided essential reagents or provided essential materials (applies to authors who contributed by providing animals, constructs, databases, etc., necessary for the research); CAD, LK analyzed data or performed statistical analysis; RC, CAD, LK, PHL, CS, JJ, OI, LPS, DD, DE, SHS wrote paper (only authors who made a major contribution); RC, SHS had primary responsibility for final content.
Corresponding author
Ethics declarations
Conflict of interest
No authors have any conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Chatterjee, R., Davenport, C.A., Kwee, L. et al. Preliminary evidence of effects of potassium chloride on a metabolomic path to diabetes and cardiovascular disease. Metabolomics 16, 75 (2020). https://doi.org/10.1007/s11306-020-01696-w
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s11306-020-01696-w